AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+38.55%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.94B
AUM Growth
+$2.94B
(+40%)
Cap. Flow
-$16M
Cap. Flow
% of AUM
-0.55%
Top 10 Holdings %
Top 10 Hldgs %
47.94%
Holding
134
New
28
Increased
21
Reduced
57
Closed
5
Top Buys
| 1 |
GDS Holdings
GDS
|
$87.6M |
| 2 |
Generation Bio
GBIO
|
$59.1M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$37.7M |
| 4 |
Royalty Pharma
RPRX
|
$36.4M |
| 5 |
NovaGold Resources
NG
|
$23.9M |
Top Sells
| 1 |
Moderna
MRNA
|
$161M |
| 2 |
Avantor
AVTR
|
$42.5M |
| 3 |
PayPal
PYPL
|
$41.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$29.6M |
| 5 |
Zillow
Z
|
$24M |
Sector Composition
| 1 | Healthcare | 75.63% |
| 2 | Consumer Discretionary | 16.28% |
| 3 | Technology | 3.84% |
| 4 | Financials | 1.19% |
| 5 | Communication Services | 0.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Moderna
MRNA
$9.37B
| $32.1M | 0.9% | 500,000 -2,500,000 | -83% | -$161M |
|
|
EPZM
27
DELISTED
Epizyme, Inc
EPZM
| $30.1M | 0.84% | 1,875,000 -425,000 | -18% | -$6.83M |
|
|
TBIO
28
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $28.7M | 0.8% | 1,600,000 +1,000,000 | +167% | +$17.9M |
|
|
29
Zillow
Z
$20.4B
| $27.8M | 0.78% | 483,000 -417,000 | -46% | -$24M |
|
|
30
NovaGold Resources
NG
$2.78B
| $23.9M | 0.67% | +2,600,000 | New | +$23.9M |
|
|
RUBY
31
DELISTED
Rubius Therapeutics, Inc
RUBY
| $23M | 0.64% | 3,852,341 -31,450 | -0.8% | -$188K |
|
|
TPTX
32
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $22.6M | 0.63% | 350,000 +50,000 | +17% | +$3.23M |
|
33
Agios Pharmaceuticals
AGIO
$2.19B
| $20.1M | 0.56% | 376,000 -24,000 | -6% | -$1.28M |
|
34
American Airlines Group
AAL
$8.82B
| $19.6M | 0.55% | +1,500,000 | New | +$19.6M |
|
35
BridgeBio Pharma
BBIO
$9.89B
| $19.6M | 0.55% | 600,000 +50,000 | +9% | +$1.63M |
|
36
Adverum Biotechnologies
ADVM
$64.6M
| $18.8M | 0.53% | 900,000 +300,000 | +50% | +$6.26M |
|
37
Mersana Therapeutics
MRSN
$36.5M
| $18.7M | 0.52% | +800,000 | New | +$18.7M |
|
38
Replimune Group
REPL
$422M
| $18.6M | 0.52% | 750,000 +150,000 | +25% | +$3.73M |
|
39
Repare Therapeutics
RPTX
$71.7M
| $18.6M | 0.52% | +600,000 | New | +$18.6M |
|
40
Bio-Techne
TECH
$8.5B
| $17.2M | 0.48% | +65,000 | New | +$17.2M |
|
41
FibroGen
FGEN
$47.8M
| $16.2M | 0.45% | 400,000 -200,000 | -33% | -$8.11M |
|
|
ARAV
42
DELISTED
Aravive, Inc. Common Stock
ARAV
| $16.1M | 0.45% | 1,380,306 -69,694 | -5% | -$811K |
|
43
Trip.com Group
TCOM
$48.2B
| $15.6M | 0.44% | 600,000 +135,000 | +29% | +$3.5M |
|
|
HARP
44
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $14.9M | 0.42% | 900,000 -300,000 | -25% | -$4.98M |
|
45
Aurinia Pharmaceuticals
AUPH
$1.58B
| $14.6M | 0.41% | 900,000 +150,000 | +20% | +$2.44M |
|
|
VNET
46
VNET Group
VNET
$2.33B
| $13.9M | 0.39% | 583,000 -417,000 | -42% | -$9.95M |
|
47
Iovance Biotherapeutics
IOVA
$807M
| $13.7M | 0.38% | 500,000 -250,000 | -33% | -$6.86M |
|
|
ALBO
48
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $13.3M | 0.37% | 500,360 -87,765 | -15% | -$2.32M |
|
49
Y-mAbs Therapeutics
YMAB
$388M
| $13M | 0.36% | 300,030 -99,970 | -25% | -$4.32M |
|
|
SWTX
50
DELISTED
SpringWorks Therapeutics
SWTX
| $12.6M | 0.35% | 300,000 -50,000 | -14% | -$2.1M |
|